Back to Discover

CELC · Industry · Nasdaq · As of 21 Nov 2026

Celcuity Inc. stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
46

Cautious · 46 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

Very high

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Fewer than eight quarters on file

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Pre-revenue — no valuation basis

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Weak

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Balanced

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Fundamental score not available. This company's filings don't yet contain enough of the measures AIR requires. AIR still assesses it on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.

Discovery Gap: Very high (93/100) · Gap confidence 72/100

Discovery gap

Documented progress is running well ahead of market attention.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: -2Slipped -2 on softer inputs.
Window31 Oct 2026 → 21 Nov 2026
Momentum-1Weighed on the score this month.

Evidence timeline

What changed — last 90 days

As of 18 Nov 2026
  1. The company launched REVTORPYK (gedatolisib) commercially on September 30, 2026, for HR+/HER2- breast cancer, with 91% of U.S. commercial/Medicare lives having coverage.

    Results · 8-K filed 5 Nov →

  2. The company filed a quarterly report for the period ending September 30, 2026.

    Quarterly/annual report · 10-Q filed 5 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Fri 26 Mar · expected 10-K

    Last year filed 26 Mar 2026.

  3. Fri 14 May · expected 10-Q

    Last year filed 14 May 2026.

  4. Filed and other evidence
  5. Thu 5 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

  6. Thu 5 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    REVTORPYK (gedatolisib) launched commercially on September 30, 2026, for HR+/HER2- breast cancer. 91% of U.S. commercial/Medicare lives have coverage; 78% of top 36 strategic accounts have ordered. Positive Phase 3 VIKTORIA-1 data for PIK3CA mutant cohort submitted as sNDA.

  7. Fri 2 Oct · 8-K

    8-K · Item 5.02 — Director or officer change

  8. Wed 30 Sep · 8-K

    8-K · Item 8.01 — Other events

  9. Wed 26 Aug · 8-K

    8-K · Item 8.01 — Other events

  10. Thu 13 Aug · 8-K

    8-K · Item 2.02 — Results of operations

  11. Thu 13 Aug · 10-Q

    Quarterly report (10-Q), period ending 30 Jun 2026

  12. Wed 15 Jul · 8-K

    8-K · Item 8.01 — Other events

  13. Tue 14 Jul · FDA

    [FDA original_approval] Celcuity Inc. — REVTORPYK (NDA219908/1) — Original NDA/BLA approval

  14. Mon 8 Jun · 8-K

    8-K · Items 1.01, 1.02, 2.03, 8.01 — Material agreement

  15. Tue 2 Jun · 8-K

    8-K · Item 8.01 — Other events

  16. Mon 18 May · 8-K

    8-K · Item 5.02 — Director or officer change

  17. Thu 14 May · 8-K

    8-K · Item 2.02 — Results of operations

  18. Thu 14 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  19. Fri 1 May · 8-K

    8-K · Item 8.01 — Other events

  20. Thu 26 Mar · 10-K

    Annual report (10-K), FY2025

  21. Wed 25 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  22. Thu 12 Feb · 8-K

    8-K · Item 5.02 — Director or officer change

Earlier →

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast. Small grey outline: other evidence on record, such as an FDA decision.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.